Amgen Inc. (AMGN)

Biotechnology company that develops and manufactures human therapeutics, focusing on areas such as oncology, cardiovascular, and inflammation.

AMGN Stock Quote

Company Report

Amgen Inc. is a prominent global biotechnology company specializing in the discovery, development, manufacturing, and distribution of human therapeutics. The company focuses on a wide spectrum of therapeutic areas including inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience.

Amgen's diverse product portfolio includes Enbrel, utilized for treating conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis. Neulasta reduces infection risks in cancer patients with low white blood cell counts. Prolia addresses osteoporosis in postmenopausal women, while Xgeva prevents skeletal-related events. Otezla treats adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers related to Beh├žet's disease. Additionally, Amgen offers Aranesp for anemia, KYPROLIS for relapsed or refractory multiple myeloma, and Repatha to lower risks of myocardial infarction, stroke, and coronary revascularization.

Amgen distributes its extensive product range to healthcare providers such as physicians, clinics, dialysis centers, hospitals, and pharmacies through pharmaceutical wholesale distributors and direct-to-consumer channels. The company has collaborative agreements with major entities including Novartis Pharma AG, UCB, Bayer HealthCare LLC, and Eli Lilly and Company, enhancing its global reach and impact in the biopharmaceutical industry.

Established in 1980 and headquartered in Thousand Oaks, California, Amgen continues to innovate through partnerships and research collaborations, exemplifying its commitment to advancing medical science and improving patient outcomes worldwide.


AMGN Revenue Chart

Stock Research


AMGN Chart

View interactive chart for AMGN

AMGN Profile


Analyst Ratings